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Background
Live attenuated vaccines are mostly appropriate for global
mass immunization, controlling very efficiently global
pandemics like polio or measles. Although a live attenu-
ated HIV vaccine is not currently considered for safety rea-
sons, a strategy based on the expression of HIV-1 particles
through a live replicating viral vector might mimic the
advantageous characteristics of live attenuated SIV.
Methods
With this aim, we generated a recombinant measles vac-
cine expressing simultaneously HIV-1 Gag and Env and
evaluated its immunogenicity in mice and macaques.
Measles vaccine is a live attenuated negative-stranded
RNA virus proven to be one of the safest and most effec-
tive human vaccines. The efficacy of recombinant mea-
sles-HIV virus was evaluated in macaques after intrarectal
SHIV challenge.
Results
In mice, the recombinant vaccine stimulated MV and HIV
antibody with neutralizing activity, as well as cellular
immunity composed of CD4 and CD8 T cells. In the
macaque/SHIV model, the vaccine induced a 2–4 log
reduction in acute viral load. More than 3 years after chal-
lenge, the macaques were sacrificed and T-cell popula-
tions were determined in different organs. We found that
CD4 central memory T cells of the gut were preserved in
vaccinated animals as compared to controls vaccinated
with empty measles. We also demonstrated that recom-
binant measles-HIV infects human professional APC,
such as dendritic and B cells, and induces efficient presen-
tation of HIV-1 epitopes to autologous T-cells and subse-
quent activation of cytokine secretion by human HIV-1
Gag-specific T-cell clones in vitro.
Conclusion
The immunogenicity of measles-HIV virus results from its
capacity to replicate in vivo after administration and to
infect productively dendritic cells. This strategy, which is
currently in the process of phase I human trial evaluation,
provides a vaccine that might protect children and adoles-
cents simultaneously from measles and HIV and be
affordable to populations through the Expanded Program
on Immunization.
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